Experimentally derived relative molar response factors and oxidized DNA base content in peripheral blood mononuclear cells of patients prior to doxorubicin
| DNA base . | Ion used . | RMRF* . | Oxidized DNA base level (nmol/mg DNA)* . | Oxidized DNA base level (oxidized bases/ 106 bases)† . |
|---|---|---|---|---|
| Thy Gly | 259 | 0.49 ± 0.13 | 5.98 ± 6.99 | 1914 ± 2237 |
| 5-OH-Hyd | 317 | — | 0.81 ± 1.25 | 259 ± 400 |
| FapyAde | 354 | 1.66 ± 0.55 | 0.64 ± 0.64 | 205 ± 205 |
| 5-OHMe-Ura | 358 | 0.31 ± 0.07 | 0.60 ± 0.85 | 192 ± 272 |
| 5,6diOH-Ura | 417 | 2.35 ± 0.87 | 1.20 ± 0.83 | 384 ± 266 |
| 5-OH-5-MeHyd | 331 | 0.40 ± 0.10 | 1.64 ± 2.66 | 525 ± 851 |
| 5-OH-Ura | 329 | 0.72 ± 0.51 | 0.60 ± 0.54 | 192 ± 173 |
| FapyGua | 442 | 8.20 ± 6.1 | 6.62 ± 6.24 | 2118 ± 1997 |
| Xan | 353 | 0.45 ± 0.30 | 4.71 ± 3.97 | 1507 ± 1270 |
| 2-OH-Ade | 352 | 0.25 ± 0.13 | 0.33 ± 0.77 | 106 ± 246 |
| 5-OH-Cyt | 328 | 0.46 ± 0.11 | 0.73 ± 0.72 | 234 ± 230 |
| 8-OH-Ade | 352 | 0.32 ± 0.12 | 1.52 ± 0.73 | 486 ± 237 |
| 8-OH-Gua | 440 | 4.66 ± 2.76 | 13.30 ± 9.76 | 4256 ± 3123 |
| DNA base . | Ion used . | RMRF* . | Oxidized DNA base level (nmol/mg DNA)* . | Oxidized DNA base level (oxidized bases/ 106 bases)† . |
|---|---|---|---|---|
| Thy Gly | 259 | 0.49 ± 0.13 | 5.98 ± 6.99 | 1914 ± 2237 |
| 5-OH-Hyd | 317 | — | 0.81 ± 1.25 | 259 ± 400 |
| FapyAde | 354 | 1.66 ± 0.55 | 0.64 ± 0.64 | 205 ± 205 |
| 5-OHMe-Ura | 358 | 0.31 ± 0.07 | 0.60 ± 0.85 | 192 ± 272 |
| 5,6diOH-Ura | 417 | 2.35 ± 0.87 | 1.20 ± 0.83 | 384 ± 266 |
| 5-OH-5-MeHyd | 331 | 0.40 ± 0.10 | 1.64 ± 2.66 | 525 ± 851 |
| 5-OH-Ura | 329 | 0.72 ± 0.51 | 0.60 ± 0.54 | 192 ± 173 |
| FapyGua | 442 | 8.20 ± 6.1 | 6.62 ± 6.24 | 2118 ± 1997 |
| Xan | 353 | 0.45 ± 0.30 | 4.71 ± 3.97 | 1507 ± 1270 |
| 2-OH-Ade | 352 | 0.25 ± 0.13 | 0.33 ± 0.77 | 106 ± 246 |
| 5-OH-Cyt | 328 | 0.46 ± 0.11 | 0.73 ± 0.72 | 234 ± 230 |
| 8-OH-Ade | 352 | 0.32 ± 0.12 | 1.52 ± 0.73 | 486 ± 237 |
| 8-OH-Gua | 440 | 4.66 ± 2.76 | 13.30 ± 9.76 | 4256 ± 3123 |